Cellular senescence is a stress-induced state of stable proliferative arrest in which cells stop dividing but remain metabolically active. Senescent cells are characterized by elevated senescence-associated beta-galactosidase activity, impaired DNA synthesis, and induction of key cell-cycle regulators such as p53, p21, and p16INK4A. While this arrest serves as a tumor-suppressive mechanism, the persistent accumulation of senescent cells over a lifetime becomes increasingly problematic. These cells secrete a cocktail of pro-inflammatory molecules known as the senescence-associated secretory phenotype, or SASP, which includes signaling proteins such as IL-6 and IL-8. The SASP promotes chronic, low-grade inflammation that has been implicated in neurodegeneration, osteoporosis, atherosclerosis, osteoarthritis, and fibrosis across multiple organ systems.

Current therapeutic strategies against senescence fall into two broad categories. Senolytic drugs, including both synthetic agents and naturally occurring flavonoids, selectively kill senescent cells, while senomorphics aim to suppress their harmful secretions. In addition, immunotherapeutic approaches such as CAR-T cells, natural killer cell therapies, B cell-based strategies, and senolytic vaccines have emerged as alternatives that target surface molecules highly expressed on senescent cells. However, existing senolytics suffer from limited specificity and intrinsic toxicity, constraining their long-term clinical application. This unmet need for precise and targeted interventions motivated the research team, led by investigators at Peking University Health Science Center, to search for new senescence-associated surface molecules that might serve as handles for future therapies.

The researchers began by examining PTCHD4 expression across multiple cellular models of senescence. In human fetal lung diploid fibroblasts known as 2BS cells, PTCHD4 mRNA and protein levels rose significantly under both genotoxic stress, induced by bleomycin treatment, and replicative stress from continuous cell passaging. This upregulation was accompanied by classic senescence markers: reduced EdU incorporation indicating diminished DNA synthesis, increased senescence-associated beta-galactosidase activity, elevated p53 and p21, and heightened SASP factor expression. Similar increases appeared in mouse embryonic fibroblasts, human umbilical vein endothelial cells, and adult retinal pigment epithelial cells, demonstrating that PTCHD4 elevation is a cell-type-independent and species-independent feature of senescence. The pattern also held in alveolar epithelial type II cells, the lung epithelial population critically involved in pulmonary fibrosis.

Crucially, the link between PTCHD4 and aging extended beyond cell culture. Immunohistochemical staining of lung, liver, kidney, and heart tissues from 90-week-old mice and from progeroid Zmpste24-deficient mice revealed increased PTCHD4 staining that broadly paralleled p16INK4A, a canonical senescence marker. Under normal physiological conditions, PTCHD4 is typically expressed at low or undetectable levels, as documented in public expression databases, which strengthened the hypothesis that the protein plays a specific role in senescent rather than healthy cells. Analysis of public human lung transcriptomic datasets added further weight: the proportion of PTCHD4-positive alveolar type II cells was increased in idiopathic pulmonary fibrosis samples compared with controls, and PTCHD4-positive epithelial cells, including aberrant basaloid cells enriched in fibrotic lungs, exhibited higher expression of senescence markers and increased SASP module scores than their PTCHD4-negative counterparts.

To determine whether PTCHD4 merely accompanies senescence or actively drives it, the team performed gain- and loss-of-function experiments. Mouse embryonic fibroblasts isolated from PTCHD4-knockout mice maintained their proliferative capacity until passage 14, displaying senescent characteristics only at that late stage, whereas wild-type cells underwent marked growth arrest and extensive senescence by passage 8. Conversely, overexpressing PTCHD4 in young fibroblasts was sufficient to induce senescence-associated phenotypes by early passage 5, including reduced proliferation, increased beta-galactosidase activity, and elevated p53, p16INK4A, and IL-6. PTCHD4 overexpression similarly pushed alveolar epithelial type II cells toward senescence. Together, these results establish PTCHD4 as a causal contributor to the senescence program rather than a passive bystander.

The physiological consequences of PTCHD4 loss were striking in animal models. In a D-galactose-induced aging-like mouse model, PTCHD4-deficient mice exhibited substantially higher locomotor activity, greater grip strength, and longer rotarod latency than wild-type controls, indicating improved physical performance. Serum biochemical analysis revealed no detectable impairments in liver or kidney function associated with the genetic deletion. Most notably, in natural aging conditions, PTCHD4-deficient mice showed a 25 percent increase in median lifespan, rising from 20 to 25 months. While the authors note this observation requires further study, it suggests that attenuating PTCHD4 signaling may meaningfully influence organismal longevity.

The disease relevance of these findings was tested in a bleomycin-induced pulmonary fibrosis model, a standard proxy for idiopathic pulmonary fibrosis, a devastating age-associated disorder that predominantly affects people over 50. Twenty-one days after bleomycin administration, wild-type mice showed markedly reduced forced vital capacity and static lung compliance, both indicators of deteriorating lung function. PTCHD4-deficient mice, however, retained significantly better pulmonary function. Sirius Red staining confirmed substantially lower collagen deposition in knockout lungs, and histological examination revealed less alveolar structural destruction and reduced inflammatory cell infiltration. Immunofluorescence analysis showed that p21-positive senescence signals in the alveolar epithelial compartment, along with bleomycin-induced upregulation of IL-6 and Cxcl2, were suppressed by PTCHD4 deficiency, indicating that the protein’s deletion dampens both the senescence response and the inflammatory cascade that fuels fibrotic remodeling.

Mechanistically, the study traced PTCHD4’s effects to the PI3K-AKT signaling pathway, a well-characterized regulator of aging whose persistent activation accelerates senescence through enhanced mTOR signaling, increased oxidative stress, and reinforced p53/p21- and p16/Rb-mediated cell-cycle arrest. Although PTCHD4 is structurally related to PTCH1, a known inhibitor of Hedgehog signaling, the researchers found that canonical Hedgehog target genes remained unchanged when PTCHD4 was manipulated. Transcriptome sequencing of young and old wild-type and knockout fibroblasts instead revealed significant downregulation of the PI3K-AKT pathway in old PTCHD4-deficient cells. Phosphorylated AKT at Ser473 was elevated in old wild-type fibroblasts but substantially lower in old knockout cells. Critically, re-expressing a constitutively active AKT construct in PTCHD4-deficient fibroblasts reversed the anti-senescence effects, restoring senescence markers and SASP expression, while dominant-negative AKT or pharmacological inhibition with MK-2206 phenocopied the protective effect of PTCHD4 deletion. Pull-down experiments suggest PTCHD4 does not physically bind AKT directly, pointing to an intermediate mechanism still to be discovered.

The study also clarifies how PTCHD4 itself is regulated during senescence. Previous work has shown that the tumor suppressor p53 transcriptionally activates PTCHD4, embedding it in a canonical senescence pathway, while recent research identified post-transcriptional control through METTL3/METTL14-mediated m6A modification and IGF2BP1-dependent mRNA stabilization in senescent cells. The authors acknowledge important limitations: the precise molecular cascade connecting PTCHD4 to AKT activation remains undefined, direct evidence from primary human tissue samples is still lacking, and the long-term, organ-specific consequences of PTCHD4 deletion require systematic safety assessment. Nevertheless, by linking a poorly characterized membrane protein to AKT signaling, lifespan, physical performance, and pulmonary fibrosis, the study provides a compelling foundation for exploring the PTCHD4-AKT axis as a therapeutic target. Given the growing arsenal of senescent-cell-targeting immunotherapies that depend on accessible surface molecules, a transmembrane protein upregulated specifically in senescent cells could prove an ideal candidate for future anti-aging medicine.

Subject of Research: Identification of the transmembrane protein PTCHD4 as a regulator of cellular senescence, aging, and age-related pulmonary fibrosis through AKT signaling

Article Title: Transmembrane Protein PTCHD4 Is a Novel Regulator of Cellular Senescence and Age‐Related Pathologies

Article References: Transmembrane Protein PTCHD4 Is a Novel Regulator of Cellular Senescence and Age‐Related Pathologies. (n.d.). https://doi.org/10.1111/acel.70711

Image Credits: AI Generated

DOI: 10.1111/acel.70711

Keywords: PTCHD4, cellular senescence, aging, AKT signaling, pulmonary fibrosis, SASP, senolytics, p53, lifespan, alveolar epithelial cells, patched domain family, Aging Cell

The work builds on a decade of genetic evidence. Genome-wide association studies have repeatedly linked variants near the desmoplakin gene, DSP, to susceptibility to idiopathic pulmonary fibrosis, and independent work has shown that a functional variant, rs2076295, regulates desmoplakin expression in airway epithelial cells. Desmoplakin variants have also been associated with a distinctly fibrotic and inflammatory form of heart muscle disease, suggesting that this protein does more than glue cells together. What has been missing, however, is a mechanistic account of how reduced desmoplakin in the alveolar epithelium could translate into the collagen deposition, matrix stiffening, and epithelial dysfunction that define pulmonary fibrosis. The new study, led by first author Pooja Singh with senior author Ritushree Kukreti, sets out to close that gap.

To do so, the researchers used small interfering RNA to silence DSP expression in A549 cells, an adenocarcinoma-derived human alveolar epithelial cell line that is a workhorse of pulmonary fibrosis modeling. The consequences of losing desmoplakin were immediate and multifaceted. The cells underwent hallmarks of epithelial-to-mesenchymal transition, the process by which epithelial cells shed their polarized, adhesive identity and acquire migratory, matrix-producing characteristics. Cell migration increased, epithelial permeability rose, and the expression of fibrotic and extracellular matrix-associated genes climbed. Among the genes upregulated were COL1A1, which encodes the alpha-1 chain of type I collagen, the dominant structural protein of fibrotic scars, and MMP9, a matrix metalloproteinase that degrades and reshapes the extracellular matrix. In fibrotic lungs, the balance between matrix-degrading enzymes and their inhibitors is famously disrupted, and the appearance of these genes after DSP loss places desmoplakin squarely upstream of matrix remodeling.

To identify the pathway responsible, the team turned to the STRING database and mapped the known interaction partners of desmoplakin, then performed pathway enrichment analysis on that network. One signal rose above the rest: the canonical Wnt/β-catenin pathway, an ancient developmental signaling cascade whose reactivation in adult tissues is a well-documented feature of idiopathic pulmonary fibrosis. Prior studies have shown that functional Wnt signaling is increased in fibrotic human lungs and that β-catenin–dependent transcription supports the survival and migration of alveolar epithelial cells after injury. The enrichment analysis suggested that desmoplakin might act as a brake on this program—and that removing the brake would allow fibrotic signaling to run unchecked.

The mechanistic validation that followed is where the study becomes technically interesting. Desmosomes are not merely mechanical fasteners; their component proteins participate in signaling crosstalk, most notably through plakoglobin, also known as γ-catenin. Plakoglobin is a close molecular relative of β-catenin: both are armadillo-family proteins that compete for overlapping binding sites at junctions, and both can, in principle, enter the nucleus and engage T-cell factor/lymphoid enhancer factor (TCF/LEF) transcription factors. Crucially, plakoglobin acts as a transcriptional antagonist of β-catenin in several tissues. Landmark work in cardiomyocytes showed that nuclear plakoglobin suppresses canonical Wnt/β-catenin signaling, and that its loss underlies the pathology of arrhythmogenic cardiomyopathy. The New Delhi team hypothesized that an analogous arrangement governs the alveolar epithelium.

The experiments supported that hypothesis. Using cycloheximide chase assays, which block new protein synthesis and allow researchers to follow the decay of existing proteins over time, the researchers found that loss of desmoplakin destabilized desmosomal complexes and accelerated the degradation of plakoglobin. At the same time, β-catenin turnover was reduced, meaning the signaling-competent catenin persisted longer in the cell. Quantitative PCR and western blotting confirmed the corresponding changes in transcript and protein abundance, and immunofluorescence microscopy revealed increased accumulation of β-catenin in the nucleus—the compartment where it acts as a transcriptional co-activator. Luciferase reporter assays, in which cells are engineered to glow when TCF/LEF-driven transcription occurs, demonstrated that this nuclear β-catenin was functionally active, driving enhanced TCF/LEF-dependent transcription. The downstream consequence was elevated expression of extracellular matrix genes, including COL1A1 and MMP9, tying the junctional protein loss directly to the fibrotic transcriptional output.

The team then tested the circuit from the opposite direction. When they overexpressed desmoplakin, Wnt/β-catenin signaling and fibrotic gene expression were suppressed, consistent with desmoplakin acting as a homeostatic restraint on the pathway. And when they pharmacologically inhibited Wnt/β-catenin signaling in cells lacking desmoplakin, the increases in ECM-associated gene expression were attenuated—strong evidence that the pathway is not merely correlated with the fibrotic phenotype but is causally required for it. Together, the gain-of-function, loss-of-function, and rescue experiments sketch a coherent model: desmoplakin stabilizes the desmosomal scaffold that retains plakoglobin; plakoglobin, in turn, competes with and restrains β-catenin; when desmoplakin disappears, plakoglobin degrades, β-catenin accumulates in the nucleus, TCF/LEF transcription surges, and the cell begins manufacturing the molecular ingredients of scar tissue.

The findings resonate with related observations in other organs and cell types. Plakophilin-2, another desmosomal protein, has been shown to restrain TGF-β1/p38 MAPK-dependent fibrotic gene expression in cardiomyocytes, and desmoplakin-deficient zebrafish models of cardiac disease show Wnt/β-catenin abnormalities that can be rescued by genetic and pharmacological intervention. The lung appears to follow the same logic: the structural apparatus of epithelial adhesion doubles as a signaling hub, and its erosion converts mechanical vulnerability into biochemical reprogramming. This dual role may explain why genetic variants that subtly lower desmoplakin expression—without abolishing it entirely—could predispose individuals to fibrosis over decades, particularly when combined with environmental insults such as microaspiration, smoke exposure, or viral injury.

The clinical implications are tantalizing but deliberately hedged. Available antifibrotic drugs for idiopathic pulmonary fibrosis slow disease progression modestly, and there is broad agreement that new targets are urgently needed. If reduced desmoplakin function is a driver of fibrotic initiation in susceptible individuals, then preserving desmosomal integrity, stabilizing plakoglobin, or dialing down β-catenin activity in the alveolar epithelium could represent alternative therapeutic strategies. Wnt pathway inhibitors are already in development for cancer and other fibrotic diseases, and the current results suggest a specific epithelial context in which such inhibitors might be beneficial. Conversely, the study complicates the picture for regenerative medicine, because β-catenin signaling is also required for lung development and epithelial repair; any therapeutic manipulation would need to distinguish between protective, transient signaling during wound healing and the chronic, dysregulated activation that drives fibrosis.

The authors are careful to frame their conclusions within the limits of the model system. A549 cells, while convenient and widely used, are a cancer-derived line with alveolar epithelial characteristics rather than genuine primary type II alveolar epithelial cells, and the entire study was conducted in vitro. Whether desmoplakin loss activates the same plakoglobin–β-catenin axis in primary human alveolar epithelial cells, in three-dimensional organoid cultures, or in animal models of fibrosis remains to be demonstrated. The team states explicitly that the disease relevance of the pathway will require validation in primary human alveolar epithelial cells and in vivo models. Nonetheless, by connecting a genetically validated IPF risk gene to a specific signaling mechanism and a concrete transcriptional output—collagen and matrix-remodeling enzymes—the study converts a statistical association into a testable biological hypothesis. It reframes the alveolar epithelium’s adhesive machinery as an active participant in epithelial–matrix crosstalk, and it suggests that the earliest seeds of pulmonary fibrosis may be planted not in the fibroblast, as long assumed, but in the structural proteins that hold the lung’s most vulnerable cells together.